Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups
Graft-versus-host disease-free relapse-free survival, which is defined as the absence of grade III–IV acute graft-versus-host disease, systemically treated chronic graft-versus-host disease, relapse, and death, is a novel, meaningful composite end point for clinical trials. To characterize risk fact...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Ferrata Storti Foundation
2016-12-01
|
| Rangatū: | Haematologica |
| Urunga tuihono: | https://haematologica.org/article/view/7916 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
